Press Releases

All Releases

Summary Toggle Celldex Presents Emerging MerTK Antibody Program at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

PDF Version

Nov 10, 2018

Antibody technology provides an exciting new approach to enhance innate immune function in cancer HAMPTON, N.J. , Nov. 10, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented data from the Company’s MerTK antibody program in a poster session today at the Society for
Read more
Summary Toggle Celldex Presents Promising Interim Data from Phase 1 Study of Differentiated CD40 Agonist CDX-1140 at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

PDF Version

Nov 9, 2018

--Well tolerated; dose dependent biological effects consistent with CD40-mediated immune cell activity-- --Program development expanded based on results observed to date-- HAMPTON, N.J. , Nov. 09, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented interim data today from
Read more
Summary Toggle Celldex Provides Corporate Update and Reports Third Quarter 2018 Results

PDF Version

Nov 7, 2018

HAMPTON, N.J. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2018 . “We made considerable progress in the third quarter, particularly in the development program for CDX-1140, our
Read more
Summary Toggle Celldex Provides Corporate Update and Reports Second Quarter 2018 Results

PDF Version

Aug 8, 2018

HAMPTON, N.J. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2018 . The Company will host a conference call at 4:30 p.m. ET today to provide an in-depth update on its pipeline and

Read more
Summary Toggle Celldex to Report Second Quarter 2018 Financial Results and Host Corporate Update Call

PDF Version

Aug 2, 2018

HAMPTON, N.J. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release second quarter 2018 financial results on Wednesday, August 8, 2018 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m.

Read more
Summary Toggle Celldex Presents Promising Data from Phase 1/2 Study of Varlilumab and Opdivo® at 2018 ASCO Annual Meeting

Celldex Presents Promising Data from Phase 1/2 Study of Varlilumab and Opdivo® at 2018 ASCO Annual Meeting 90.9 KB

Jun 2, 2018

-- CDX-3379 also featured in a "clinical trials in progress" presentation -- HAMPTON, N.J., June 02, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today presented two programs at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Read more
Summary Toggle Celldex Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

Celldex Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference 14 KB

Jun 1, 2018

HAMPTON, N.J., June 01, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, will present a corporate overview at the Jefferies 2018 Global Healthcare Conference on June 7, 2018 at 3:00 p.m.
Read more
Summary Toggle Celldex Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Celldex Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 13.3 KB

May 16, 2018

HAMPTON, N.J., May 16, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that two abstracts will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2018 in Chicago.
Read more
Summary Toggle Celldex Provides Corporate Update and Reports First Quarter 2018 Results

Celldex Provides Corporate Update and Reports First Quarter 2018 Results 42.3 KB

May 10, 2018

HAMPTON, N.J., May 10, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2018. "Celldex has made considerable progress on an important strategic prioritization of our pipeline, following
Read more
Summary Toggle Data from Multiple Celldex Programs Presented at American Association for Cancer Research (AACR) Annual Meeting 2018

PDF Version

Apr 20, 2018

-- Early data from investigator-initiated pilot study of CDX-301/radiation therapy combination in patients with advanced NSCLC show promising effect on tumor burden even in non-irradiated tumors -- -- Additional four posters at AACR Annual Meeting support ongoing Phase 2 study of CDX-3379, Phase 1

Read more

Investor Relations Contacts

Press Releases

All Releases

About us

Our Pipeline

Investor Relations Contacts

Press Releases

Search:

All Releases

About us

Our Pipeline